BioGenerator Ventures

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

SentiAR, Inc. is a digital health company based in St. Louis, Missouri, specializing in 3D augmented reality solutions for interventional medical procedures. Founded in 2017 as a spin-off from Washington University, SentiAR has developed a platform that offers real-time holographic visualization of patients' anatomical structures and catheter locations. This technology integrates data from CT, MRI, and real-time mapping systems to create a controllable 3D holographic interface. The platform aims to enhance the delivery of care by allowing clinicians to visualize complex cardiac anatomy directly over the patient, thereby improving the treatment of cardiac arrhythmias during catheterization procedures. SentiAR is in the process of preparing its platform for submission to the FDA.

Cadre Bioscience, LLC, founded in 2019 and located in Saint Louis, Missouri, focuses on developing therapeutics for various human diseases. The company is dedicated to accelerating the development of early-stage therapeutic assets by implementing a strategic plan that emphasizes de-risking and advancing these innovations. Cadre Bioscience aims to raise capital and attract skilled management to support its development initiatives, ultimately facilitating the commercialization of its technology to improve patient outcomes.

Healthy Bytes, Inc. develops a software platform that facilitates personalized nutritional counseling, connecting physicians, employers, and patients. Founded in 2014 and headquartered in Saint Louis, Missouri, with an additional office in New York, the company employs registered dietitians who provide consultations to employees seeking medical care for conditions such as obesity, diabetes, high blood pressure, and cardiovascular diseases. The platform enables users to book private consultations and allows dietitians to monitor their clients' eating habits. By leveraging existing medical benefits, employees can access nutritional counseling without incurring additional costs, promoting healthier lifestyles through expert dietary guidance.

Plastomics Inc. is a biotechnology company specializing in chloroplast genetic engineering to enhance crop performance. Founded in 2016 and based in St. Louis, Missouri, the company focuses on gene stacking and rapid breeding to improve yield production and nutritional quality. Its innovative technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, facilitating the development of more effective biotech crops. This approach not only addresses current industry challenges but also eliminates cross-pollination, enabling clients to achieve trait expression in plants more reliably. Additionally, Plastomics' unique method of maternal inheritance streamlines breeding timelines and reduces costs, making it a valuable partner for seed companies in the agricultural sector.

Aggio, LLC is an information technology company based in Saint Louis, Missouri, with an additional location in Madison, New Jersey. Founded in 2016, Aggio specializes in cloud-based sales applications tailored for the agriculture industry. The company's platform offers marketing and sales analytics that assist clients in making data-driven decisions through data harmonization and visualization. Aggio's software enables businesses to gain a comprehensive view of the market by integrating multiple data sources, facilitating effective engagement with customers and channel partners across both online and offline channels. This approach allows users to visualize and track key performance indicators, promoting faster decision-making processes.

Arch Innotek, LLC is a biotechnology company based in St. Louis, Missouri, focused on engineering microorganisms to produce natural ingredients that promote health for both humans and animals. Established in 2013, the company specializes in the fermentation of yeast to generate natural carotenoid antioxidants and other high-value molecules for the food, feed, pharmaceutical, and cosmetics industries. Arch Innotek employs sustainable and cost-effective fermentation processes to develop innovative technologies that provide healthier alternatives for consumers. Additionally, the company offers a range of scientific services, including HPLC analysis, LC-MS analysis, protein purification, and molecular cloning, to support its research and development efforts.

Canopy Biosciences, founded in 2016 and headquartered in St. Louis, Missouri, is a biotechnology company specializing in research tools for genetic engineering, molecular biology, and personalized medicine. The company offers a comprehensive range of products and services designed to facilitate gene editing, gene expression analysis, and bioprocessing. One of its key technologies, TUNR, targets translation elongation by inserting polyA tracks into specific coding regions of the genome, effectively reducing mRNA levels and suppressing protein expression. This innovative approach supports biomedical researchers at universities, research institutions, and within the biotechnology and pharmaceutical sectors, accelerating scientific discovery and enhancing the field of genetic engineering. Canopy Biosciences operates as a subsidiary of Bruker Corporation.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Atomation is a company that specializes in developing an Internet of Things (IoT) platform designed to connect existing legacy objects and assets to the internet. Founded in 2014 and headquartered in Saint Louis, Missouri, with origins in Tel Aviv, Israel, Atomation focuses on transforming data gathered from sensors into actionable insights. Its platform supports various sectors, including agriculture, medical, industrial, and logistics, by enabling devices to interact, analyze information, and make real-time decisions. Atomation offers both software and hardware development kits, providing businesses with affordable and straightforward solutions to enhance their operations and optimize their performance.

Plastomics Inc. is a biotechnology company specializing in chloroplast genetic engineering to enhance crop performance. Founded in 2016 and based in St. Louis, Missouri, the company focuses on gene stacking and rapid breeding to improve yield production and nutritional quality. Its innovative technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, facilitating the development of more effective biotech crops. This approach not only addresses current industry challenges but also eliminates cross-pollination, enabling clients to achieve trait expression in plants more reliably. Additionally, Plastomics' unique method of maternal inheritance streamlines breeding timelines and reduces costs, making it a valuable partner for seed companies in the agricultural sector.

SentiAR, Inc. is a digital health company based in St. Louis, Missouri, specializing in 3D augmented reality solutions for interventional medical procedures. Founded in 2017 as a spin-off from Washington University, SentiAR has developed a platform that offers real-time holographic visualization of patients' anatomical structures and catheter locations. This technology integrates data from CT, MRI, and real-time mapping systems to create a controllable 3D holographic interface. The platform aims to enhance the delivery of care by allowing clinicians to visualize complex cardiac anatomy directly over the patient, thereby improving the treatment of cardiac arrhythmias during catheterization procedures. SentiAR is in the process of preparing its platform for submission to the FDA.

CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

MedSocket offers a clinical decision support system aimed at enhancing the efficiency and quality of patient care. The company has developed a patented 1-Click Decision Support (1-CDS) system and a medical search engine known as 1-Search, both designed by clinicians to address their specific needs. These technologies facilitate quick and easy access to evidence-based information for busy healthcare providers, thereby aiming to improve healthcare decisions, reduce errors, and enhance patient outcomes. Successful pilots of these systems at the University of Missouri Health System have demonstrated their potential to decrease healthcare costs and improve the overall efficiency of patient consultations. Founded in 2012 by Dr. Karl Kochendorfer, who recognized the necessity for immediate information access in clinical settings, MedSocket combines expertise in business and information science to refine clinical decision-making processes.

Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic drugs. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, Italy, and South Korea, GeneriCo focuses on niche generic pharmaceuticals that are often overlooked by larger competitors. The company targets foundational medicines in key therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. GeneriCo distinguishes itself through its expertise in complex formulations and embedded drug delivery technologies, addressing market needs that are typically neglected by mid-sized and large generic firms. The company's global reach enables it to serve a diverse customer base.

NeuroLutions Inc. is a company based in St. Louis, Missouri, focused on developing brain-computer interface (BCI) devices aimed at restoring functions for patients disabled due to neurological injuries, particularly stroke survivors. Founded in 2007, NeuroLutions employs non-invasive electroencephalography (EEG) technology to capture brain activity without the need for implanted electrodes. The EEG data is wirelessly transmitted to a tablet, where it is analyzed to interpret the patient's intended muscle movements. This innovative approach enables users to facilitate muscle re-education and helps maintain or improve their range of motion, thereby enhancing rehabilitation outcomes for individuals with movement impairments.

SanusEO, LLC is a mobile health technology company based in St. Louis, Missouri, specializing in a text-based patient engagement platform (PEP) designed to enhance communication between patients and care teams. Founded in 2012, SanusEO's platform supports healthcare providers, chronic disease patients, and payers by delivering daily alerts and real-time data to care teams, facilitating both immediate and long-term intervention strategies. The platform is particularly effective for managing patients transitioning from hospital care and those newly diagnosed with chronic conditions. By utilizing mobile texting programs, SanusEO aims to modify patient behaviors related to medication adherence, vital monitoring, diet, physical activity, and overall communication with healthcare providers. The approach targets various chronic diseases, including diabetes and congestive heart failure, and offers multi-language capabilities to cater to diverse patient populations.

CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.

RNAgri is a company based in St. Louis, Missouri, that specializes in innovative technology for producing ribonucleic acid (RNA). Founded in 2011, the company focuses on addressing the challenges associated with the large-scale production of exogenous RNA interference (RNAi) products. By utilizing a large-scale fermentation process, RNAgri enables farmers to enhance the protection and growth of their crops and livestock through the cost-efficient production of RNA. This technology aims to improve agricultural practices and contribute to more sustainable farming solutions.

SynerZ Medical, Inc. develops medical device for the treatment of obesity and type 2 diabetes. The company was incorporated in 2013 and is based in St. Louis, Missouri.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and located in Columbia, Missouri, the company has created a proprietary drug product designed to function as a minimally invasive therapeutic cancer vaccine. This product is administered through intratumoral injection following tumor ablation, leveraging tumor-associated neoantigens to stimulate a systemic anti-tumor immune response. By transforming the process of tumor ablation into a therapeutic approach, ImmunoPhotonics aims to enhance treatment options for patients with late-stage metastatic cancers. The company has also established a strategic partnership with Veterinary Cancer Therapeutics, LLC to further its mission in cancer treatment.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

MedSocket offers a clinical decision support system aimed at enhancing the efficiency and quality of patient care. The company has developed a patented 1-Click Decision Support (1-CDS) system and a medical search engine known as 1-Search, both designed by clinicians to address their specific needs. These technologies facilitate quick and easy access to evidence-based information for busy healthcare providers, thereby aiming to improve healthcare decisions, reduce errors, and enhance patient outcomes. Successful pilots of these systems at the University of Missouri Health System have demonstrated their potential to decrease healthcare costs and improve the overall efficiency of patient consultations. Founded in 2012 by Dr. Karl Kochendorfer, who recognized the necessity for immediate information access in clinical settings, MedSocket combines expertise in business and information science to refine clinical decision-making processes.

Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and located in Columbia, Missouri, the company has created a proprietary drug product designed to function as a minimally invasive therapeutic cancer vaccine. This product is administered through intratumoral injection following tumor ablation, leveraging tumor-associated neoantigens to stimulate a systemic anti-tumor immune response. By transforming the process of tumor ablation into a therapeutic approach, ImmunoPhotonics aims to enhance treatment options for patients with late-stage metastatic cancers. The company has also established a strategic partnership with Veterinary Cancer Therapeutics, LLC to further its mission in cancer treatment.

Tansna Therapeutics, Inc. is a drug discovery and development company based in St. Louis, Missouri, founded in 2010. The company specializes in creating and commercializing oral drugs aimed at treating epilepsy and other central nervous system disorders. Its primary focus is on developing novel oral anticonvulsant agents designed to effectively reduce seizure frequency in patients with epilepsy. By providing safe and innovative treatment options, Tansna Therapeutics aims to enhance the quality of care for individuals suffering from these debilitating conditions.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic drugs. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, Italy, and South Korea, GeneriCo focuses on niche generic pharmaceuticals that are often overlooked by larger competitors. The company targets foundational medicines in key therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. GeneriCo distinguishes itself through its expertise in complex formulations and embedded drug delivery technologies, addressing market needs that are typically neglected by mid-sized and large generic firms. The company's global reach enables it to serve a diverse customer base.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, founded in 2008. The company specializes in developing a rapid and label-free biological assay platform that measures clinical and point-of-care samples. This innovative platform employs diagnostic arrayed imaging reflectometry (AIR) to enable the simultaneous detection of hundreds of analytes from a single drop of fluid, allowing healthcare professionals to conduct sophisticated tests with high sensitivity and specificity. By significantly reducing the time required for testing, Adarza BioSystems aims to enhance diagnostic capabilities in various healthcare settings.

MediBeacon Inc. is a medical technology company specializing in real-time kidney function monitoring solutions. Founded in 2012 and based in St. Louis, Missouri, the company develops innovative optical diagnostic systems aimed at enhancing patient care. Its flagship product, the NIC-Kidney device, allows for the monitoring of glomerular filtration rate (mGFR) in preclinical settings. MediBeacon also offers a renal function system that combines an optical skin sensor with a proprietary fluorescent agent, enabling continuous real-time monitoring of kidney function. This technology is particularly beneficial in intensive care units and operating rooms, where it helps clinicians optimize patient outcomes and dosing strategies. The company has a robust intellectual property portfolio that includes additional product concepts for physiological monitoring and imaging of pathological diseases, positioning it as a leader in nephrology and optical diagnostics.

Tansna Therapeutics, Inc. is a drug discovery and development company based in St. Louis, Missouri, founded in 2010. The company specializes in creating and commercializing oral drugs aimed at treating epilepsy and other central nervous system disorders. Its primary focus is on developing novel oral anticonvulsant agents designed to effectively reduce seizure frequency in patients with epilepsy. By providing safe and innovative treatment options, Tansna Therapeutics aims to enhance the quality of care for individuals suffering from these debilitating conditions.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

RNAgri is a company based in St. Louis, Missouri, that specializes in innovative technology for producing ribonucleic acid (RNA). Founded in 2011, the company focuses on addressing the challenges associated with the large-scale production of exogenous RNA interference (RNAi) products. By utilizing a large-scale fermentation process, RNAgri enables farmers to enhance the protection and growth of their crops and livestock through the cost-efficient production of RNA. This technology aims to improve agricultural practices and contribute to more sustainable farming solutions.

ARTA Bioscience, Inc is developing new therapeutics for prostate cancer and inflammatory diseases. Current treatments for prostate cancer are insufficient and the disease is the second leading cause of cancer deaths among American men. ARTA's technology involves an entirely different approach to combating disease compared to traditional treatments. In addition to prostate cancer, the company's technologies may be used to target other important proteins in the nuclear receptor class. The company has established operations at the BioGenerator Accelerator Labs. ARTA's technology was developed by Dr. Marc Diamond at Washington University.

Mobius Therapeutics, LLC is a developer of sterile injectable pharmaceutical products focused on ophthalmic applications in the United States. Founded in 2006 and based in St. Louis, Missouri, the company offers Mitosol, a kit that provides a safe method for reconstituting and transferring mitomycin, an antifibrotic agent used in glaucoma, refractive, and corneal surgeries. Additionally, Mobius Therapeutics produces Amphadase, a hyaluronidase injection. The company serves ophthalmologists and their patients by providing products that enhance surgical outcomes and patient care. Its offerings are available for purchase online, and the company is actively pursuing regulatory approval for its products, with further developments in the pipeline.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

PixelEXX Systems Inc. is a company specializing in the development of innovative imaging devices aimed at cancer diagnosis. Founded in 2008 and headquartered in Saint Louis, Missouri, the company focuses on creating advanced nanoarrays that capture molecular signals related to cellular activity. Their proprietary technology features novel nano resonant photodiodes that enhance sensitivity and allow the capture of both wavelength and polarization information without the need for additional components like microlenses or filters. This approach enables clients to optimize imaging and sensing capabilities while reducing size, weight, and power consumption.

APT Therapeutics is a biotechnology company based in St. Louis, Missouri, focused on developing innovative antiplatelet therapies. The company aims to transform human apyrase into a life-saving medicine through advanced techniques in protein engineering, protein informatics, and cheminformatics software. APT Therapeutics' therapies target critical medical conditions such as acute myocardial infarction, stroke, and complications arising from transplantation. By enhancing the effectiveness of these treatments, the company seeks to minimize damage to patients during heart attacks and improve their overall outcomes.